Core Viewpoint - Eupraxia Pharmaceuticals Inc. has announced a public offering of 12,727,273 common shares at a price of US$5.50 per share, aiming to raise approximately US$70 million for advancing its product pipeline and other corporate purposes [1][3] Group 1: Offering Details - The offering consists of 12,727,273 common shares priced at US$5.50 each, with gross proceeds expected to be around US$70 million before expenses [1] - Underwriters have a 30-day option to purchase an additional 1,909,090 common shares under the same terms [1] - The offering is set to close on September 24, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds will primarily fund the advancement of the product pipeline, including ongoing preclinical studies, clinical trials, regulatory submissions, and commercial preparation [3] - Additional allocations will support research and development of new pipeline candidates, business development initiatives, and general corporate purposes [3] - The company may also invest in expanding its intellectual property portfolio and enhancing corporate infrastructure for future growth [3] Group 3: Regulatory and Compliance - The offering is made under a U.S. registration statement declared effective by the SEC and the existing Canadian short form base shelf prospectus [4] - A preliminary prospectus supplement has been filed with securities commissions in Canada and the SEC in the U.S., with a final supplement to follow [4][5]
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares